000			02125nam a2200469 i 4500
999			_c280276 _d280276
001			on1090541314
003			OCoLC
005			20190423081337.0
007			he bmb024bbca
008			190325s2018 dcu bb f000 0 eng c
040			_aPUCPR _beng _erda _cGPO _dMvI
042			_apcc
043			_an-us---
074			_a1042-B (MF)
086	0		_aY 4.F 49/20:115-76
088			_aSerial no. J-113-58 (United States. Congress. Senate. Committee on the Judiciary)
099			_aY 4.J 89/2:S.HRG.113-886
110	1		_aUnited States. _bCongress. _bSenate. _bCommittee on the Judiciary,
245	1	0	_aOversight of the Drug Enforcement Administration : _bhearing before the Committee on the Judiciary, United States Senate, One Hundred Thirteenth Congress, second session, April 30, 2014.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2018.
300			_aiii, 63 pages ; _c24 cm.
336			_btxt
337			_bh _2rdamedia
338			_bhe _2rdacarrier
490	1		_aS. hrg. ; _v113-886
500			_aShipping list no.: 2019-0064-M.
500			_a"Serial no. J-113-58."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
533			_aMicrofiche. _b[Washington, D.C.] : _cU.S. Government Printing Office, _d[2018] _e1 microfiche : negative.
776	0	8	_iPrint version: _aUnited States. Congress. Senate. Committee on the Judiciary. _tOversight of the Drug Enforcement Administration _w(OCoLC)1061150287
776	0	8	_iOnline version: _aUnited States. Congress. Senate. Committee on the Judiciary. _tOversight of the Drug Enforcement Administration _w(OCoLC)1061504188
810	1		_aUnited States. _bCongress. _bSenate. _tS. hrg. ; _v113-886.
050		4	_aKF26 _b.J8 2014n
610	1	0	_aUnited States. _bDrug Enforcement Administration.
650		0	_aDrug control _zUnited States.
650		0	_aDrug abuse _zUnited States _xPrevention.
650		0	_aOpioid abuse _zUnited States _xPrevention.
650		0	_aDrugs _xPrescribing _zUnited States _xManagement.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8